Kuckelman, Novos senior vice president and general counsel, said Novo welcomes competition grounded in science, but it cannot stand by as advertising continues to withhold the information patients need, saying Lillys misleading ads leave patients with the mistaken impression that Lilly's drugs are vastly superior, and that is simply not true. In a statement earlier this week, Lilly said it stood by its ads, calling them "truthful," "transparent" and grounded in the most direct scientific evidence available - exactly what patients deserve. What Did Novo Nordisk Allege In Its Lawsuit
Microdosing weight-loss drugs currently has no clear evidence base, but if a person wants to attempt it, they should do so with the full knowledge of their treating team
[1] It's important to note that missing a single dose occasionally is unlikely to cause serious harm for most patients, but your blood glucose levels may be less well controlled during this period
Gray market sources are unregulated
Definitions of pediatric pancreatitis and survey of present clinical practices
